HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis

BACKGROUND: Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has scarcely been studied. OBJECTIVE: The study aims to assess whether fing...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenfeld Kan, S, Staun-Ram, E, Golan, D, Miller, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794658/
https://www.ncbi.nlm.nih.gov/pubmed/31662882
http://dx.doi.org/10.1177/2055217319882720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794658/
https://www.ncbi.nlm.nih.gov/pubmed/31662882
http://dx.doi.org/10.1177/2055217319882720

Ejemplares similares